


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (original) Formula (I) compounds:



I

where:

A is CX; alkanylidene with 2 to 4 carbon atoms, particularly CH₂-CH;
alkenyldiene with 2 to 4 carbon atoms, particularly CH=C;

Ar is monocyclic or bicyclic C₆-C₁₀ aryl or heteroaryl, containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen and sulphur, possibly substituted by halogens, NO₂, OH, C₁-C₄ alkyl and alkoxy, said alkyl and alkoxy possibly substituted by at least one halogen; monocyclic, bicyclic or tricyclic arylalkyl or heteroarylalkyl containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen and sulphur, where the alkyl residue contains from 1 to 3 carbon atoms, said arylalkyl or heteroarylalkyl possibly substituted by halogens, NO₂, OH, C₁-C₄ alkyl and alkoxy,

said alkyl and alkoxy possibly substituted by at least one halogen;

f is the number 0 or 1;

h is the number 0 or 1;

m is a whole number from 0 to 3;

n is the number 0 or 1 and if n is 0, R₁ is absent, and COY is directly bound to benzene);

Q and Z, which may be the same or different, are selected from the group consisting of NH, O, S, NHC(O)O, NHC(O)NH, NHC(O)S, OC(O)NH, S(CO)NH, C(O)NH, and NHC(O);

R is selected from R₂, OR₂;

R₁ is selected from H, COW, SO₃⁻, OR₃, =O, CN, NH₂, NHCO(C₆-C₁₀)Ar, where Ar may possibly be substituted by halogens, NO₂, OH, C₁-C₄ alkyl and alkoxy, said alkyl and alkoxy possibly substituted by at least one halogen;

R₂ is selected from H, straight or branched C₁-C₄ alkyl, possibly substituted by at least one halogen;

R₃ is selected from H, straight or branched C₁-C₄ alkyl, possibly substituted by at least one halogen, (C₆-C₁₀)ArCH₂, where Ar is possibly substituted by halogens, NO₂, OH, C₁-C₄ alkyl and alkoxy, said alkyl and alkoxy possibly substituted by at least one halogen;


W is selected from OH, OR₄, NH₂;

R₄ is straight or branched C₁-C₄ alkyl;

Y is selected from OH, OR₅, NH₂;

R₅ is straight or branched C₁-C₄ alkyl;

or A, COY and R₁ together form a cycle of the type:



their pharmacologically acceptable salts, racemic mixtures, individual enantiomers, geometric isomers or stereoisomers, and tautomers.

2. (original) Compounds according to claim 1, in which Ar is a heteroaryl, preferably containing nitrogen as the heteroatom, and preferably f is 0, m is 1 or 2, Q is oxygen, and R is hydrogen.

3. (original) Compounds according to claim 1, in which Ar is an aryl, possibly substituted by one or more halogen atoms, alkyl, alkoxy or lower haloalkyl, nitro, mono- or di-alkylamine, and preferably f is 0, m is 0, 1 or 2, Q is oxygen or HNC(O)O, and R is hydrogen.

4. (currently amended) Compounds according to ~~one of claims 13~~ claim 1, where R₁ is COW.

5. (original) Compound according to claim 1, selected from the group consisting of:

- i. Diethyl 4- [2-(1 -indolyl)ethoxy]benzylidenemalonate;
- ii. Diethyl 4-[2-(1-indolyl)ethoxy]benzylmalonate;
- iii. Dimethyl 4-[2-(1-indolyl)ethoxy]benzylidenemalonate;
- iv. Dimethyl 4-[2-(1-indolyl)ethoxy]benzylmalonate;
- v. 4-[2-(1-indolyl)ethoxy]benzylmalonic acid;
- vi. Methyl (2S) -amino-2- [4-[2-(1-indolyl)ethoxy]phenyl]-acetate;
- vii. Methyl 4-[2-(1-indolyl)ethoxy]benzoate;
- viii. Methyl 3-[4-[2 -(1-indolyl)ethoxy]phenyl]propanoate;
- ix. Methyl 2-[4-[2-(1-indolyl)ethoxy]phenyl]acetate;
- x. Methyl 2-sulpho-2- [4-[2-(1-indolyl)ethoxy]phenyl]acetate sodium salt;
- xi. Methyl (S)-2-benzoylamino-2-[4-[2-(1-indolyl)ethoxy]-phenyl] acetate;
- xii. Methyl 2-hydroxy-3-[4- [2-(1-indolyl)ethoxy]phenyl]-propanoate;

- xiii. Dimethyl 4-[2-[4-(dimethylamino)phenyl]ethoxy]benzylmalonate;
- xiv. Methyl 3-[4-[2-(1-indolyl)ethoxy]phenyl]-2-cyano-propenoate;
- xv. Methyl 3-[4-[2-(1-indolyl)ethoxy]phenyl]-2-cyano-propanoate;
- xvi. Dimethyl 4-[2-(3-indolyl)ethoxy]benzylidenemalonate;
- xvii. Dimethyl 4-[2-(1-naphthyl)ethoxy]benzylmalonate;
- xviii. Dimethyl 4-[2-(2-pyridyl)ethoxy]benzylmalonate;
- xix. Dimethyl 4-[2-(4-chlorophenyl)ethoxy]benzylmalonate;
- xx. 5-[4-[2-(4-chlorophenyl)ethoxy]phenylmethylene]-thiazolidine-2,4-dione;
- xxi. 5-[4-[2-(4-chlorophenyl)ethoxy]phenylmethyl]thiazolidine-2,4-dione;
- xxii. Dimethyl 3-[2-(4-chlorophenyl)ethoxy]benzylmalonate;
- xxiii. Dimethyl 3-[2-(phenyl)ethoxy]benzylmalonate;
- xxiv. Dimethyl 3-[N-(4-trifluoromethylbenzyl)carbamoyl]-4-methoxybenzylmalonate;
- xxv. Dimethyl 4-methoxy-3-[2-(4-chlorophenyl)ethoxy]benzyl-malonate;
- xxvi. Dimethyl 3-(2-phenylethoxy)-4-methoxy benzylmalonate;
- xxvii. Dimethyl 4-[2-(4-methoxyphenyl)ethoxy]benzylmalonate;
- xxviii. Dimethyl 4-[3(4-methoxyphenyl)propyloxy]benzyl-malonate;
- xxix. Dimethyl 4-[2-(2-naphthyl)ethoxy]benzylmalonate;
- xxx. (2S)-2-benzoylamino-3-[4-[(4-methoxybenzyl)-carbamoyl]-oxyphenyl]ethyl propanoate;
- xxxi. Dimethyl 4- [[(4-methoxybenzyl)carbamoyl]oxy]benzyl-malonate;
- xxxii. Dimethyl 4- [[(4-trifluorotolyl)carbamoyl]oxy]benzyl-malonate;
- xxxiii. Dimethyl 4-[[[(2,4-dichlorophenyl)carbamoyl]oxy]benzyl-malonate;

- xxxiv. Dimethyl 4-[[[(4-chlorophenyl)carbamoyl]oxy]benzyl-malonate;
- xxxv. Dimethyl 4-[2-(pyridinio)ethoxy]benzylmalonate methanesulphonate;
- xxxvi. Dimethyl 4-[[[(4-nitrophenyl)carbamoyl]oxy]benzyl-malonate;
- xxxvii. Dimethyl 3- [[[(4-methoxybenzyl)carbamoyl]oxy]benzylmalonate;
- xxxviii. Dimethyl 3-[[[(4-butylphenyl)carbamoyl]oxy]benzyl-malonate;
- xxxix. Dimethyl 4-[[[(4-butylphenyl)carbamoyl]oxy]benzyl-malonate;
- xl. Dimethyl 3-[[[(4-chlorophenyl)carbamoyl]oxy]benzyl-malonate;
- xli. (Z)-2-ethoxy-3-[4-[2-(4-chloro-phenyl)ethoxy]-phenyl] ethyl propenoate;
- xl. (E)-2-ethoxy-3-[4-[2-(4-chloro-phenyl)ethoxy]-phenyl]ethyl propenoate;
- xl. (R,S)-2-ethoxy-3- [4-[2- (phenyl)ethoxy]phenyl]ethyl propanoate;
- xl. (R,S)-2-ethoxy-3-[4-[2-(4-chloro-phenyl)ethoxy]-phenyl-]methyl propanoate;
- xl. Dimethyl 4- [2-(2,3-dimethyl-1-indolyl)ethoxy]benzyl-malonate.
6. (currently amended) Compounds according to ~~claims 1-5~~ claim 1 as medicines.
7. (currently amended) Pharmaceutical compositions containing at least one compound according to ~~claims 1-5~~ claim 1 in mixtures with pharmaceutically acceptable vehicles and/or excipients.
8. (currently amended) Use of the compounds according to ~~claims 1-5~~ claim 1 for the preparation of a medicine with serum glucose and serum lipid lowering activity.
9. (currently amended) Use of the compounds according to ~~claims 1-5~~ claim 1 for the preparation of a medicine for the prophylaxis and treatment of diabetes, particularly type 2, and its complications, Syndrome X, the various forms of insulin resistance and hyperlipidaemias.